PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men

Trial Profile

PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms PROUD
  • Most Recent Events

    • 04 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 23 Sep 2015 Results published in the Internet Document.
    • 06 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top